Seres Therapeutics, Inc. Other Nonoperating Income (Expense)
Seres Therapeutics, Inc. (MCRB) reported Other Nonoperating Income (Expense) of $673.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:OtherNonoperatingIncomeExpense · last filed 2026-08-05
- Seres Therapeutics, Inc. other nonoperating income (expense) for the quarter ending 2026-06-30 was $673.00K, a 84.33% decline year-over-year.
- Seres Therapeutics, Inc. other nonoperating income (expense) for the quarter ending 2026-03-31 was $669.00K, a 90.60% decline year-over-year.
- Seres Therapeutics, Inc. other nonoperating income (expense) for the quarter ending 2025-12-31 was $2.50M, a 64.67% decline year-over-year.
- Seres Therapeutics, Inc. other nonoperating income (expense) for the quarter ending 2025-09-30 was $2.84M.
- Seres Therapeutics, Inc. other nonoperating income (expense) for fiscal 2025 was $16.75M.
- Seres Therapeutics, Inc. other nonoperating income (expense) for fiscal 2024 was -$14.11M, a 10627.61% decline from fiscal 2023.
- Seres Therapeutics, Inc. other nonoperating income (expense) for fiscal 2023 was $134.00K.
- Seres Therapeutics, Inc. other nonoperating income (expense) for fiscal 2022 was -$705.00K.
| Period end | Other Nonoperating Income (Expense) 3 month | Other Nonoperating Income (Expense) 3 month as first filed | Other Nonoperating Income (Expense) 6 month | Other Nonoperating Income (Expense) 6 month as first filed | Other Nonoperating Income (Expense) 9 month | Other Nonoperating Income (Expense) 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $673.00K 10-Q · filed 2026-08-05 | $1.34M 10-Q · filed 2026-08-05 | $3.84M derived: sum of 3 quarters · filed 2026-08-05 | $6.68M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2026-03-31 | $669.00K 10-Q · filed 2026-05-05 | $3.17M derived: sum of 2 quarters · filed 2026-05-05 | $6.01M derived: sum of 3 quarters · filed 2026-05-05 | $10.30M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-12-31 | $2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $5.34M derived: sum of 2 quarters · filed 2026-03-12 | $9.64M derived: sum of 3 quarters · filed 2026-08-05 | $16.75M 10-K · filed 2026-03-12 | ||
| 2025-09-30 | $2.84M 10-Q · filed 2025-11-05 | $7.14M derived: sum of 2 quarters · filed 2026-08-05 | $14.26M 10-Q · filed 2025-11-05 | $21.33M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-06-30 | $4.29M 10-Q · filed 2026-08-05 | $11.41M 10-Q · filed 2026-08-05 | $18.49M derived: sum of 3 quarters · filed 2026-08-05 | -$4.03M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-03-31 | $7.12M 10-Q · filed 2026-05-05 | $14.20M derived: sum of 2 quarters · filed 2026-05-05 | -$8.32M derived: sum of 3 quarters · filed 2026-05-05 | -$6.88M derived: sum of 4 quarters · filed 2026-05-05 | ||
| 2024-12-31 | $7.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$15.44M derived: sum of 2 quarters · filed 2026-03-12 | -$13.99M derived: sum of 3 quarters · filed 2026-03-12 | -$14.11M 10-K · filed 2026-03-12 | ||
| 2024-09-30 | -$22.52M 10-Q · filed 2025-11-05 | -$21.07M derived: sum of 2 quarters · filed 2025-11-05 | -$21.18M 10-Q · filed 2025-11-05 | -$20.23M derived: sum of 4 quarters · filed 2026-03-12 | ||
| 2024-06-30 | $1.45M 10-Q · filed 2025-08-06 | $692.00K 10-Q · filed 2024-08-13 | $1.33M 10-Q · filed 2025-08-06 | $3.16M 10-Q · filed 2024-08-13 | $2.29M derived: sum of 3 quarters · filed 2026-03-12 | $3.29M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-03-31 | $505.00K 10-Q · filed 2025-05-07 | $2.47M 10-Q · filed 2024-05-08 | $841.00K derived: sum of 2 quarters · filed 2026-03-12 | $1.84M derived: sum of 3 quarters · filed 2026-03-12 | $329.00K derived: sum of 4 quarters · filed 2026-03-12 | |
| 2023-12-31 | $336.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.33M derived: sum of 2 quarters · filed 2026-03-12 | -$176.00K derived: sum of 3 quarters · filed 2026-03-12 | $134.00K 10-K · filed 2026-03-12 | ||
| 2023-09-30 | $999.00K 10-Q · filed 2024-11-13 | -$512.00K derived: sum of 2 quarters · filed 2024-11-13 | -$202.00K 10-Q · filed 2024-11-13 | -$225.00K derived: sum of 4 quarters · filed 2025-03-13 | ||
| 2023-06-30 | -$1.51M 10-Q · filed 2024-08-13 | -$1.20M 10-Q · filed 2024-08-13 | -$1.22M derived: sum of 3 quarters · filed 2025-03-13 | -$1.26M derived: sum of 4 quarters · filed 2025-03-13 | ||
| 2023-03-31 | $310.00K 10-Q · filed 2024-05-08 | $287.00K derived: sum of 2 quarters · filed 2025-03-13 | $254.00K derived: sum of 3 quarters · filed 2025-03-13 | -$50.00K derived: sum of 4 quarters · filed 2025-03-13 | ||
| 2022-12-31 | -$23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$56.00K derived: sum of 2 quarters · filed 2025-03-13 | -$360.00K derived: sum of 3 quarters · filed 2025-03-13 | -$705.00K 10-K · filed 2025-03-13 | ||
| 2022-09-30 | -$33.00K 10-Q · filed 2023-11-02 | -$337.00K derived: sum of 2 quarters · filed 2023-11-02 | -$682.00K 10-Q · filed 2023-11-02 | -$998.00K derived: sum of 4 quarters · filed 2024-03-05 | ||
| 2022-06-30 | -$304.00K 10-Q · filed 2023-08-08 | -$649.00K 10-Q · filed 2023-08-08 | -$965.00K derived: sum of 3 quarters · filed 2024-03-05 | -$1.00M derived: sum of 4 quarters · filed 2024-03-05 | ||
| 2022-03-31 | -$345.00K 10-Q · filed 2023-05-09 | -$661.00K derived: sum of 2 quarters · filed 2024-03-05 | -$696.00K derived: sum of 3 quarters · filed 2024-03-05 | -$981.00K derived: sum of 4 quarters · filed 2024-03-05 | ||
| 2021-12-31 | -$316.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | -$351.00K derived: sum of 2 quarters · filed 2024-03-05 | -$636.00K derived: sum of 3 quarters · filed 2024-03-05 | -$1.04M 10-K · filed 2024-03-05 | ||
| 2021-09-30 | -$35.00K 10-Q · filed 2022-11-02 | -$320.00K derived: sum of 2 quarters · filed 2022-11-02 | -$729.00K 10-Q · filed 2022-11-02 | -$937.00K derived: sum of 4 quarters · filed 2023-03-07 | ||
| 2021-06-30 | -$285.00K 10-Q · filed 2022-08-03 | -$694.00K 10-Q · filed 2022-08-03 | -$902.00K derived: sum of 3 quarters · filed 2023-03-07 | -$557.00K derived: sum of 4 quarters · filed 2023-03-07 | ||
| 2021-03-31 | -$409.00K 10-Q · filed 2022-05-04 | -$617.00K derived: sum of 2 quarters · filed 2023-03-07 | -$272.00K derived: sum of 3 quarters · filed 2023-03-07 | $204.00K derived: sum of 4 quarters · filed 2023-03-07 | ||
| 2020-12-31 | -$208.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $137.00K derived: sum of 2 quarters · filed 2023-03-07 | $613.00K derived: sum of 3 quarters · filed 2023-03-07 | $981.00K 10-K · filed 2023-03-07 | ||
| 2020-09-30 | $345.00K 10-Q · filed 2021-11-10 | $821.00K derived: sum of 2 quarters · filed 2021-11-10 | $1.19M 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | $476.00K 10-Q · filed 2021-08-03 | $844.00K 10-Q · filed 2021-08-03 | ||||
| 2020-03-31 | $368.00K 10-Q · filed 2021-05-04 | |||||
| 2019-12-31 | $1.07M 10-K · filed 2022-03-01 | |||||
| 2017-09-30 | -$123.00K 10-Q · filed 2017-11-08 | -$340.00K derived: sum of 2 quarters · filed 2018-08-02 | -$699.00K 10-Q · filed 2017-11-08 | |||
| 2017-06-30 | -$217.00K 10-Q · filed 2018-08-02 | -$576.00K 10-Q · filed 2018-08-02 | ||||
| 2017-03-31 | -$359.00K 10-Q · filed 2017-05-04 | |||||
| 2016-09-30 | -$312.00K 10-Q · filed 2017-11-08 | -$580.00K derived: sum of 2 quarters · filed 2017-11-08 | -$620.00K 10-Q · filed 2017-11-08 | |||
| 2016-06-30 | -$268.00K 10-Q · filed 2017-08-03 | -$324.00K 10-Q · filed 2017-08-03 | ||||
| 2016-03-31 | -$56.00K 10-Q · filed 2017-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |